Robert Barrow Sells 29,208 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 29,208 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Definium Therapeutics Price Performance

Shares of DFTX traded up $0.16 during mid-day trading on Friday, reaching $44.95. 12,203,314 shares of the stock traded hands, compared to its average volume of 2,289,586. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.01. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -18.05 and a beta of 2.37. The firm has a fifty day moving average price of $24.13 and a 200 day moving average price of $19.18.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). As a group, equities research analysts predict that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on DFTX. Robert W. Baird raised their price target on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday. Canaccord Genuity Group set a $60.00 target price on Definium Therapeutics in a report on Monday. Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Finally, Piper Sandler restated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Definium Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $47.08.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DFTX. Palumbo Wealth Management LLC lifted its position in Definium Therapeutics by 18.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock valued at $522,000 after purchasing an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in Definium Therapeutics in the 4th quarter worth $117,000. Bay Rivers Group increased its stake in Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock worth $214,000 after buying an additional 2,000 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Definium Therapeutics in the 3rd quarter worth $107,000. Finally, Caxton Associates LLP purchased a new position in shares of Definium Therapeutics in the third quarter valued at about $126,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.